Cardiorenalmetabolic

SURPASS-CVOT data show fewer deaths or HF events with tirzepatide vs dulaglutide in patients with HF, driven largely by mortality.

Two inSPire2026 posters detail how health system specialty pharmacy teams support patients with ATTR-CM.

Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.

The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."

A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.

Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

Moderate coffee intake may lower cardiovascular risk, but energy drinks may harm the heart.

The approval is based on findings from the phase 3 SCOUT-HCM trial.

A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.

HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.

Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.

Mark Belkin, MD, explains why HFpEF goes undiagnosed, how MRA evidence should guide therapy, and what's next for AI-driven care.

The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.

The first study of its kind links nighttime light exposure to structural heart changes among over 11,000 adults followed for 3 years.

Cleveland heart failure experts discuss the new HFpEF pathway, CKM screening gaps, and drug access barriers.

A random survival forest model trained on 850 patients outperformed the Mayo Clinic and National Amyloidosis Centre staging systems for ATTR-CM.

PVI for intermittent claudication was associated with more than double the rate of major adverse limb events and higher costs of care.

Late-breaking HELIOS-B subgroup data show mortality and CV benefits held regardless of baseline tafamidis use, per results at ESC Congress 2026.

Keith Bellovich, DO, of Strive Health, discusses how the new CKM guideline unifies cardiology, nephrology, and endocrinology care.

Five-year EXPLORER-LTE data show sustained LVOT gradient reductions and NYHA class improvements in patients with obstructive HCM.

A VESALIUS-CV analysis found a 20% reduction in all-cause death with evolocumab in patients without prior MI or stroke, emerging after 1.5 years.

FUSION trial data published show FFRCT added to CCTA safely cut unnecessary catheterizations.

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

The phase 4 study will track serum transthyretin and other biomarkers in 50 adults with ATTR-CM switching from tafamidis to acoramidis over 6 months.